Drugs / TAA-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03652545 | Dec 2018 → Mar 2028 expected | brain neoplasm | Catherine Bollard | Active not recruiting | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAA-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03652545 ↗ |
| Modality | Cell therapy | “autologous, nongenetically engineered T cells” PMID 42380677 ↗ Jun 2026 |
| Route | Other | “systemically administered trivalent T cells” PMID 42380677 ↗ Jun 2026 |
| Target | PRAME | “autologous, systemically administered trivalent T cells targeting WT1, PRAME and survivin” PMID 42380677 ↗ Jun 2026 |
| Target | WT1 | “autologous, systemically administered trivalent T cells targeting WT1, PRAME and survivin” PMID 42380677 ↗ Jun 2026 |